Quantitative proteomics reveal three potential biomarkers for risk assessment of acute myocardial infarction. Issue 3 (1st March 2022)

• Record Type: Journal Article
• Authors: Xie, Yao; Zhang, Hongzhou; Huang, Tieqiu
• Is Part Of: Bioengineered. Volume 13:Issue 3(2022)
• Page Start: 4939
• Page End: 4950
• Publication Date: 2022-03-01
• Subjects: Proteomics -- acute myocardial infarction -- biomarker -- exosome; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2022.2037365
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Acute myocardial infarction (AMI) is the one of the main cause of death worldwide. Exosomes carry important information about intercellular communication and could be diagnostic marker for many diseases. Here, we aimed to find potential key proteins for the early diagnosis of AMI. A label free proteomics strategy was used to identify the differentially expressed proteins (DEPs) of AMI patients' plasma exosome. By bioinformatics analysis and enzyme-linked immunosorbent assay to validate the candidate proteins. Compared to healthy control plasma exosome, we totally identified 72 differentially expressed proteins (DEPs) in AMI patients. Also, we found that complement and coagulation cascades was activated by KEGG analysis and GSEA. PLG, C8B and F2 were selected as candidate molecules for further study, and then validated another 40 plasma samples using enzyme-linked immunosorbent assay. Finally, we found that the expression levels of these three proteins (PLG, C8B and F2) were significantly higher than those of healthy controls (P < 0.05). ROC analysis revealed that PLG, C8B and F2 had potential value for AMI early diagnosis. In conclusion, our study identified three potential biomarkers for AMI diagnosis. But there remains a need to further study the mechanism of the biomarkers. GRAPHICAL ABSTRACT: uf0001